COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies
Open Access
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODYThe Lancet Rheumatology, 2023
- Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health SystemJAMA Network Open, 2023
- COVID‐19 vaccine response in patients with hematologic malignancy: A systematic review and meta‐analysisAmerican Journal of Hematology, 2022
- Overview of Sankey flow diagrams: Focusing on symptom trajectories in older adults with advanced cancerJournal of Geriatric Oncology, 2022
- A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccinationClinical & Translational Immunology, 2022
- Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort studyThe Lancet Haematology, 2021
- Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myelomaCancer Cell, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)The Lancet Infectious Diseases, 2019
- Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)The Lancet Infectious Diseases, 2019